CUPISCO : A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18+Age Over 18

Cancer of<br/>Unknown PrimaryCancer LocationCancer of
Unknown Primary

Systemic therapy | CUPCancer of Unknown Primary

Trial Overview Read MoreRead more

This phase II trial is comparing molecular-guided therapy with standard platinum-containing chemotherapy for the treatment of advanced cancers of the unknown primary (CUP).
 

This trial is treating patients with cancer of the unknown primary (CUP).

This is a cancer of the unknown primary (CUP).

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy

Commercial Sponsor

Hoffmann-La Roche

Summary

Eligible participants will be assigned to receive either a molecular-guided therapy based on their genomic profile OR a standard chemotherapy (containing Carboplatin or Cisplatin in combination with Gemcitabine or Paclitaxel), which will be the active comparator to the intervention arm of the trial.

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Enquiries Line Coordinator
clinicaltrials.enquiries@petermac.org
03 8559 7456 (9am-2pm, Mon-Fri)

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next